Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb:44:109-117.
doi: 10.1016/j.jare.2022.04.013. Epub 2022 Apr 28.

Urinary 20-HETE: A prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney disease

Pamela Houeiss  1 , Rachel Njeim  1 , Hani Tamim  2 , Ahmed F Hamdy  3 , Tanya S Azar  1 , William S Azar  4 , Mohamed Noureldein  1 , Youssef H Zeidan  5 , Awad Rashid  3 , Sami T Azar  6 , Assaad A Eid  7
Affiliations

Urinary 20-HETE: A prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney disease

Pamela Houeiss et al. J Adv Res. 2023 Feb.

Abstract

Introduction: The identification and validation of a non-invasive prognostic marker for early detection of diabetic kidney disease (DKD) can lead to substantial improvement in therapeutic decision-making.

Objectives: The main objective of this study is to assess the potential role of the arachidonic acid (AA) metabolite 20-hydroxyeicosatetraenoic (20-HETE) in predicting the incidence and progression of DKD.

Methods: Healthy patients and patients with diabetes were recruited from the Hamad General Hospital in Qatar, and urinary 20-HETE levels were measured. Data analysis was done using the Statistical Package for Social Sciences (SPSS).

Results: Our results show that urinary 20-HETE-to-creatinine (20-HETE/Cr) ratios were significantly elevated in patients with DKD when compared to patients with diabetes who did not exhibit clinical signs of kidney injury (p < 0.001). This correlation was preserved in the multivariate linear regression accounting for age, diabetes, family history of kidney disease, hypertension, dyslipidemia, stroke and metabolic syndrome. Urinary 20-HETE/Cr ratios were also positively correlated with the severity of kidney injury as indicated by albuminuria levels (p < 0.001). A urinary 20-HETE/Cr ratio of 4.6 pmol/mg discriminated between the presence and absence of kidney disease with a sensitivity of 82.2 % and a specificity of 67.1%. More importantly, a 10-unit increase in urinary 20-HETE/Cr ratio was tied to a 10-fold increase in the risk of developing DKD, suggesting a 20-HETE prognostic efficiency.

Conclusion: Taken together, our results suggest that urinary 20-HETE levels can potentially be used as non-invasive diagnostic and prognostic markers for DKD.

Keywords: 20-HETE; Biomarkers; Diabetes; Diabetic Kidney Diseases; Macrovascular Complications; Microvascular Complications.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Schematic of Study Design.
Fig. 2
Fig. 2
20-HETE as a Potential Diagnostic Tool, The illustrated ROC curves suggest 20-HETE as a potential diagnostic marker for kidney injury. Selection of 20-HETE levels of 6.4 pmol/mg (A) shows a sensitivity of 77.1.9%, a specificity of 78.6% and an AUC of 0.84 in detecting kidney injury in all subjects. B: In detecting albuminuria, 20-HETE levels of 4.6 pmol/mg had a sensitivity of 82.2% and a specificity of 67.1% with an AUC of 0.81. C: In diagnosing DKD, urinary 20-HETE/Cr ratio is one of the variables that allow for the detection of kidney disease in patients with diabetes with an AUC of 0.97, a sensitivity of 92.9% and a specificity of 99.5%.
See this image and copyright information in PMC

References

    1. Hussain S., Jamali M.C., Habib A., Hussain M.S., Akhtar M., Najmi A.K. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clin Epidemiol Global Health. 2021;9:2–6.
    1. Amatruda M., Gembillo G., Giuffrida A.E., Santoro D., Conti G. The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies. Medicina. 2021;57(9):868. - PMC - PubMed
    1. Giandalia A., Giuffrida A.E., Gembillo G., Cucinotta D., Squadrito G., Santoro D., et al. Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors. Int J Mol Sci. 2021;22(11):5808. - PMC - PubMed
    1. Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018;63:177–186. - PMC - PubMed
    1. de Zeeuw D., Remuzzi G., Parving H.-H., Keane W.F., Zhang Z., Shahinfar S., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320. - PubMed

Publication types

Substances